
|Videos|August 26, 2021
Role of Second Generation FLT3 Inhibitors in AML
Expert examines the status of second-generation FLT3 inhibitors in newly diagnosed AML patients and the challenge with comparing clinical trial efficacy endpoints.
Advertisement
Episodes in this series

Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
'Beyond Weight Loss': Emerging Studies Show How GLP-1 Receptor Agonists May Impact Addiction Behaviors
2
New Drug Approach Targets KRAS-Mutant Lung Cancer to Overcome Therapy Resistance
3
FDA Approves Denosumab Biosimilars Boncresa and Oziltus for Osteoporosis-, Cancer-Related Bone Loss
4
Ultra-Processed Food Consumption May Worsen Breast Cancer Outcomes Among Black Women
5










































































































































































































